Download PDF
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2021; 11(03): 164-169
DOI: 10.1055/s-0041-1726685
Original Article

Aberrant DNA Methylation in Bladder Cancer among Saudi Arabia Population

Amna Shoaib Siddiqui
1   Department of Anatomy and Genetics, College of Medicine, Al Faisal University, Riyadh, Kingdom of Saudi Arabia
,
Faizah A Alshehri
2   Office of Research and Innovation ORI, Alfaisal University, Riyadh, Kingdom of Saudi Arabia
,
Ahmed Yaqinuddin
1   Department of Anatomy and Genetics, College of Medicine, Al Faisal University, Riyadh, Kingdom of Saudi Arabia
› Author Affiliations
› Further Information
   Permissions and Reprints

Corrected by:

Erratum to: Aberrant DNA Methylation in Bladder Cancer among Saudi Arabia PopulationJournal of Health and Allied Sciences NU 2022; 12(02): 221-221
DOI: 10.1055/s-0042-1742782

Abstract

Tumor biomarkers developed based on the aberrant deoxyribonucleic acid (DNA) methylation patterns in bladder cancer (BC) hold great promise due to their stability, specificity, and known associations with the disease. No study has investigated DNA methylation patterns in BC patients from Saudi population. We analyzed DNA methylation levels of 48 tumor suppressor genes loci in 24 bladder tissues (19 BC and 5 control samples) using Human Tumour Suppressor Genes EpiTect Methyl II Complete PCR Array (Qiagen, Hilden, Germany). We identified significant difference in DNA hypermethylation levels at E2F1, ERBB2, HIC1, OPCML, SFN, SFRP1, SFRP2, SPARC, and TERT gene loci between controls and cancerous samples. SCGB3A1 was differentially methylated in nonmuscle invasive versus muscle invasive BC samples. Results suggest that these aberrant DNA methylation patterns in BC are disease and population specific and can be developed as distinct DNA methylation-based biomarkers for BC detection.

Keywords

bladder cancer - DNA hypermethylation - biomarkers - DNA methylation patterns - epigenetic - tumor - MSP


Publication History

Article published online:
11 May 2021

© 2021. Nitte (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 El-Siddig AA, Albasri AM, Hussainy AS, Alhujaily AS. Urinary bladder cancer in adults: a histopathological experience from Madinah, Saudi Arabia. J Pak Med Assoc 2017; 67 (01) 83-86
    PubMedGoogle Scholar
  • 2 Oeyen E, Hoekx L, De Wachter S, Baldewijns M, Ameye F, Mertens I.. Bladder cancer diagnosis and follow-up: The current status and possible role of extracellular vesicles. International Journal of Molecular Sciences 2019; 20 (04) 821
    CrossrefPubMedGoogle Scholar
  • 3 Gurung PMS, Barnett AR, Wilson JS. et al Prognostic DNA methylation biomarkers in high-risk non-muscle-invasive bladder cancer: a systematic review to identify loci for prospective validation. Eur Urol Focus 2020; 6 (04) 683-697
    CrossrefPubMedGoogle Scholar
  • 4 Larsen LK, Lind GE, Guldberg P, Dahl C. DNA-methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of DNA, and detection technologies. Int J Mol Sci 2019; 20 (11) E2657
    CrossrefPubMedGoogle Scholar
  • 5 Martinez VG, Munera-Maravilla E, Bernardini A. et al Epigenetics of bladder cancer: where biomarkers and therapeutic targets meet. Front Genet 2019; 10: 1125
    CrossrefPubMedGoogle Scholar
  • 6 Yu Y, Cao H, Zhang M, Shi F, Wang R, Liu X. Prognostic value of DNA methylation for bladder cancer. Clin Chim Acta 2018; 484: 207-212
    CrossrefPubMedGoogle Scholar
  • 7 Turner BM. Epigenetic responses to environmental change and their evolutionary implications. Philos Trans R Soc Lond B Biol Sci 2009; 364 (1534) 3403-3418
    CrossrefPubMedGoogle Scholar
  • 8 Carja O, MacIsaac JL, Mah SM. et al Worldwide patterns of human epigenetic variation. Nat Ecol Evol 2017; 1 (10) 1577-1583
    CrossrefPubMedGoogle Scholar
  • 9 Callahan CL, Wang Y, Marian C. et al DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study. Epigenetics 2016; 11 (09) 643-652
    CrossrefPubMedGoogle Scholar
  • 10 Cree IA, Uttley L, Buckley Woods H. et al UK Early Cancer Detection Consortium. The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. BMC Cancer 2017; 17 (01) 697
    CrossrefPubMedGoogle Scholar
  • 11 Garrigou S, Perkins G, Garlan F. et al A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem 2016; 62 (08) 1129-1139
    CrossrefPubMedGoogle Scholar
  • 12 Constâncio V, Nunes SP, Henrique R, Jerónimo C. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells 2020; 9 (03) 624
    CrossrefPubMedGoogle Scholar
  • 13 Casadio V, Molinari C, Calistri D. et al DNA methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res 2013; 32: 94
    CrossrefPubMedGoogle Scholar
  • 14 Duarte-Pereira S, Paiva F, Costa VL. et al Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer 2011; 47 (07) 1106-1114
    CrossrefPubMedGoogle Scholar
  • 15 Shan M, Zhang L, Liu Y. et al DNA methylation profiles and their diagnostic utility in BC. Dis Markers 2019; 2019: 6328503
    CrossrefPubMedGoogle Scholar
  • 16 Negraes PD, Favaro FP, Camargo JL. et al DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 2008; 8 (01) 238
    CrossrefPubMedGoogle Scholar
  • 17 Zhou X, Zhang P, Han H, Lei H, Zhang X. Hypermethylated in cancer 1 (HIC1) suppresses bladder cancer progression by targeting yes-associated protein (YAP) pathway. J Cell Biochem 2019; 120 (04) 6471-6481
    CrossrefPubMedGoogle Scholar
  • 18 Duarte-Pereira S, Paiva F, Costa VL. et al Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer 2011; 47 (07) 1106-1114
    CrossrefPubMedGoogle Scholar
  • 19 Dai D, Dong X-H, Cheng S-T, Zhu G, Guo X-L. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis. Tumour Biol 2014; 35 (08) 8209-8216
    CrossrefPubMedGoogle Scholar